After graduation he got $4 Million from Vertex Pharma co-founder Rich Aldrich and started picking biotech stocks at RA. In addition, Michael served on the firm's Luxembourg Board of Directors where he was responsible for accounting and financial reporting. Scott joins RA Ventures (RAVen) as Venture Partner and will be focusing on new company creation. Alex is an Associate with the TechAtlas division of RA Capital Management. Tom is a Senior Operations Analyst at RA Capital Management. Andrew Levin is a Partner and Managing Director on the Investment Team at RA Capital Management and spearheads a drug discovery effort that has led to the formation of several new companies. Anthony has a BS in Molecular and Cellular Biology from University of Arizona and a PhD in Genetics and Molecular Biology from University of North Carolina at Chapel Hill. His research investigated chromatin structure and transcription factor binding. Previously, Tess held finance leadership roles at Foghorn Therapeutics, Wave Life Sciences, and Biogen. Ryan has a BS in Business Administration with a concentration in Accounting and Sports Management from Isenberg School of Management at University of Massachusetts, Amherst. Let us know if you like it and we may post more pieces with this option.) Most recently, Joe led the administration and support of all Apple products at Curriculum Associates as an IT Systems Engineer. Megan has a BS in Microbiology & Cell Science from University of Florida. Mariagrace has a BS in Sociology from Suffolk University. Prior to RA, he served in a dual role at Merck Research Laboratories (MRL). He has over 20 academic publications, inventorship on numerous patents, and serves as reviewer for multiple journals and NIH grants committee. Prior to RA Capital, Tom worked as an Associate at Flagship Pioneering. His doctoral research focused on breast cancer metastasis. Natalie Camacho is an Executive Assistant at RA Ventures (RAVen). Christy has an MS in Immunology from National Taiwan University, a PhD in Immunology and Microbial Pathogenesis from Cornell University, and a mini-MBA in BioPharma Innovation from Rutgers Business School. We owe a debt to the people who have mentored us, and we in turn have a responsibility to turn our hard won lessons into a solid foundation for our industry's emerging innovators and leaders.. Prior to management consulting, Mr. Grau was Director of Marketing & Business Development at a clinical information technology startup. Cosmass academic research has been published in journals such as Cell, Science, and Nature. Tom has a BA in Business Administration from St. Anselm College and earned both his Chartered Financial Analyst and Chartered Alternative Investment Analyst designations. Angela also gained experience in prior roles as Clinical Trial Manager at Roche, Sarepta, and other companies, and Clinical Research Coordinator at Tufts Medical Center and Dana-Farber Cancer Institute. Cristinas primary responsibility is to identifying compelling opportunities to help facilitate new company creation and early stage investing. Prior to this, she served as Director, Talent Acquisition and Operations at Flagship Pioneering, a role in which she built talent systems to support the growth of 30+ pre-series B biotech startup companies. He worked previously as the Director of Business Systems at Bain Capital Credit, and as a Senior Systems Analyst at eSecLending, LLC. Rajeev Shah is a Managing Partner at RA Capital Management. He was also responsible for initiating the transition of the autoimmunity strategy from one based on systemic immunosuppression to a targeted immunomodulation approach. From 2016-2017, Scott served as President of Sojournix, Inc., an asset-focused biopharmaceutical company that he co-founded and served as Board member until 2021. She previously served as Senior Vice President, R&D Operations & New Product Planning at Epirium Bio. Davids primary responsibility is to oversee the development and implementation of treasury functions for the firm. Prior to joining RA Capital, Emilie was a Vice President of Investor Relations at THL Credit. Fuad Naser is a Senior Associate with the TechAtlas division of RA Capital Management. Previously, Michael worked closely with the Investment Team, to originate conviction in potential investments by identifying breakthroughs and putting data into context, as well as advising RA's portfolio companies on many aspects of program and pipeline strategy. Emilys primary responsibility at RA Capital isdesigning and overseeing the brand management for RA Capital's internal and external communications as well assisting with the brand identity forportfolio companiesfounded through RA Capital's incubator, RA Ventures. She holds a BA in Public Administration with a minor in International Affairs from Texas State University. Zach previously worked as a Science Officer at the California Institute for Regenerative Medicine. Prior to Relay, she worked as an Executive Assistant at Bullhorn, Inc. Phi holds an Associate in Science Business Administration from Middlesex Community College. Before entering the life science space, Kat held various accounting roles in the retail industry and started her career at Ernst & Young. Sarah joined our team from MPM Capital where she served as the COO & General Counsel. Prior to RA, Anthony completed the Biopharmaceutical Leadership Development Program at Reata Pharmaceuticals. Prior to RA, Michael was a Special Projects Manager at Baupost, LLC where he led a large project to transition the business model to utilize third party fund administration, including management of the implementation. Prior to Mirai Advisory, he held a Financial Analyst role at Wainwright Investment Counsel. Erichs primary responsibilities are to drive internal and external strategic and diligence initiatives and oversee the workflow and professional development of TechAtlas Associates. Bracketts primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Harvey is a Controller at RA Capital Management. Peter Kolchinsky, Founder and Managing Director of RA Capital Management, L.P. and Founder of the nonprofit No Patient Left Behind, sits down with Liked by Peter Kolchinsky We need YOU to help. Fuads primary responsibility at RA Capital is to create competitive landscapes of drugs and medical devices for disease indications and capabilities. Peter's age is in line with some of the older Vanderpump Rules cast members, like Jax, Tom Sandoval, and Tom Schwartz. Prior to RAVen, Natalie served as an EA for three years at Massachusetts Technology Collaborative (MassTech), a Boston agency supporting business formation and growth in the state's technology sector. Before pursuing an M.B.A. at Harvard Business School, Michael received his M.D. Tom has more than nine years of operations experience. Michaels primary responsibility at RA Capital is to start and maintain relationships with current and potential investors. Prior to BEV, Kyle was a Principal at In-Q-Tel, the strategic investment arm of the CIA and US Intelligence Community, where he invested in early stage manufacturing, materials, energy, computing, and defense companies. Camerons primary responsibility is to conduct research and analysis for competitive landscapes of drugs and medical devices across a range of disease indications and capabilities. Shannon has a BA in Special Education and English from Bridgewater University and a MS in Elementary Education from Boston College. Her primary responsibilities are to provide strategic administrative support and to assist the co founder in various external and internal projects She previously held Senior Executive Assistant roles at Genuity Science and Charles River Laboratories, and served as Director of Operations at Gloucester Graphics, Inc. Amber has a dual BA concentration in International Business & Modern Languages from Northeastern University and studied abroad at American University of Paris. Prior to RAVen, Scott was President and Managing Director of The Branta Group LLC, a healthcare company formation, capital investment, and strategic advisory firm known for taking an active management role with its clients and portfolio companies in the biotechnology, medical device, diagnostics, venture capital, and private equity sectors. in Immunology from National Taiwan University College of Medicine, and a PhD in Biomedical Science from The Ohio State University. Pieter has been recognized as one of the outstanding leaders in the U.S. through his selection as a White House Fellow, and he currently serves on the Board of Directors of the White House Fellows Foundation. Most recently, she was as an Entrepreneur-in-Residence at RA Ventures and was a Scientific Co-Founder and Associate Director of Corporate Development at Athenen Therapeutics (merged into Eliem Therapeutics; ELYM). Alex comes to RA from Mirai Advisory, where he specialized in financial risk and data science and developed machine learning algorithms to support banks managing regulatory and operational challenges. Prior to Flywire, she worked as an Executive/Personal Assistant at Spark Capital. Previously, Danielle was an Associate at RA Capital, and worked in IP and tech licensing at Seven Bridges Genomics and the MIT Technology Licensing Office, respectively. Kriti Subramanyam is an Associate within the TechAtlas division of RA Capital Management. Peter Balogh is an Analyst on the Investment Team at RA Capital Management. Tim was hired as the fourth employee at Proteon and built a team that brought an innovative biologic for blood vessel remodeling from pre-clinical through two Phase 3 clinical trials. Jeff Breay is a Head Trader at RA Capital Management. Milind has co-authored more than 80 scientific articles, is co-inventor on 30 patents, and is a frequent speaker at international scientific conferences. Additionally, he is the interim CTO and Board Observer at New Equilibrium Bio. Angela's primary responsibilities at RAVen are to lead development and oversee implementation of best practices in clinical strategies in RA's newcos and portfolio companies. Robert received his BS in mechanical engineering from the University of Houston. Under his leadership, Therapeutics Alliances advanced 40+ projects, including 11 projects partnered with biopharma or new startups such as Repare Therapeutics and GliXogen Therapeutics. From time to time we may post specific open positions, but more often we will create positions for the right people. Prior to KPMG, Ryan worked at Morris and Morris, P.C. Michael's previous experience includes venture development at Health Wildcatters Seed Accelerator and product development in various roles at the Institute for Environmental and Exercise Medicine and as an Aerospace Medicine Clerk at NASA. Brett holds a BS from Washington University, St. Louis and a JD from Duquesne University School of Law and is admitted to practice law in PA. Brett previously served as a Clerk for the Washington County Court of Common Pleas in PA. Emilie Schleer is the Senior Investor Relations Manager with the Operations Team at RA Capital Management. Kyle Teamey joins RA Capital as a Managing Partner, Planetary Health. Brian Lewandowski is an Analyst on the Investment Team at RA Capital Management. Raj is active in both public and private investments in companies developing drugs, medical devices, diagnostics, and research tools. Brendan has more than 18 years of experience as a tax professional. Walter's primary responsibility at RA Capital is to create competitive landscapes of biotechnology and planetary health. 239 Kelton St, Allston, MA . He worked with Dr. David Raulet and Nobel Laureate Dr. James Allison before which he received a PhD in Molecular Oncology and BSc in Biochemistry from McGill University in Montreal. He has more than 15 years of experience in investing, company formation, and company leadership across all stages of drug development, from discovery through commercialization. Previously in his career, he served as Associate General Counsel at Millennium Pharmaceuticals (now Takeda Oncology) where he built the legal department and led internal legal activities supporting several transformative pharmaceutical partnerships, a substantial global patent estate, and the companys IPO. Daniel Grau, an experienced biotech entrepreneur and operating executive, currently serves as CEO and Director at Avilar Therapeutics, a leading extracellular protein degradation company. Cristina has nearly a decade of experience in the biotech and life sciences industries. Prior to Epirium, she was an investor on the Biotech Team at Longitude Capital. Kathryn Meng is an Investment Director within the Planetary Health division of RA Capital. Ana holds an MPH in Epidemiology and Biostatistics from Boston University School of Public Health and a BA in Neuroscience from Boston University. Jaime is an Executive Assistant at RA Ventures (RAVen). Prior to RA, Kevin was a postdoctoral associate at the Broad Institute of MIT and Harvard and an EMBO fellow. She previously worked as a Finance Associate at the MFA Companies. Anurag holds a BSE in Biomedical Engineering and a BS in Economics from Duke University. Brian's primary responsibility at RA Capital is to manage the firm's IT Operations needs. In this role, he will work to evaluate and incubate early-stage therapeutic programs. and Novus Biologicals. Gabe Fox is an Associate with the TechAtlas division of RA Capital Management. Christina holds a PhD in Neuroscience from the Ichan School of Medicine at Mount Sinai and a BS in Biochemistry from Stockholm University. Her graduate research investigated novel epigenetic regulators in glioblastoma. Prior to that, he held roles as Executive Vice President, Global Head Specialty Medicine and Vice President, Ophthalmology/Global Launch Team Head, EYLEA. Brett Scheller is a Compliance Officer at RA Capital Management. Habib Dable is a Venture Partner at RA Ventures (RAVen), focusing on advising and supporting newcos, portfolio companies and executives within RAVen. Danielle received her PhD in Neuroscience from the Massachusetts Institute of Technology. Sophie led the cell therapy program, working with teams across the Trust to build capabilities to deliver industry and academically sponsored complex cell therapy trials for solid tumor cancer patients. Ed holds a PhD in neuroscience from the University of California Berkeley, an MS in psychology from Villanova University, and a BA from La Salle University. Michael received his undergraduate degree at Georgetown University and his medical degree at the Medical University of South Carolina. Matthew Feresten is a Business Systems Analyst at RA Capital Management. Sonia Kartha is an Associate with the TechAtlas division of RA Capital Management. He earned an MS in chemical engineering and his MBA and PhD in engineering systems from MIT. Kathryn has a BS in Exercise and Health Science from the University of Massachusetts Boston. This ground-breaking new book, The Great American Drug Deal: A New Prescription for Innovative and Affordable Medicines (January 20, 2020), by Peter Kolchinsky, PhD, examines the healthcare landscape through the lens of the biotech social contract with America - the implicit agreement between the biopharmaceutical industry and American society - including the government's role in inventing . While at Johns Hopkins, she spent two years as a Research Intern and Teaching Assistant in the Department of Biology and the Department of Chemistry. Kathryn holds a BA in Geography and Peace and Conflict Studies from Colgate University, a MSc in International Development: Environment and Development from the University of Manchester (UK), and a MA and Ph.D. in Geography from Clark University (2016). He has served on the Board of Directors of Sojournix, Inc., AltusPharmaceuticals (Nasdaq: ALTU) and the CellScape Corporation. As President, U.S. Pharmaceuticals at Bayer, he directed a multi-billion-dollar portfolio of products across multiple therapeutic areas (cardiovascular disease, hematology, neurology, oncology, and women's health). Prior to her Managing Director role at NVF, Nandita held various positions at Novartis in Business Development and Licensing and as a key member of the Kymriah Global Program Team, helping to bring this novel cell therapy to market.
peter kolchinsky age